Both SOB102 and SOB101 belong to a series of the proprietary platform technology of engineered exosome drug delivery system. These nanobody-based immune checkpoint antibody (Anti-HLA-G) molecules are expressed on the outer bilayer of exosomes through genetic engineering modifications. SOB102 specific binds on HLA-G expressing tumor cells for delivering chemotherapeutic or nucleic acid drugs to tumor cells, enhancing the specificity of exosomes towards tumors and reducing the toxicity of loaded drugs to normal tissue cells.
Glioblastoma multiforme (GBM), a type of brain cancer, has a poor prognosis due to the high expression of O6-methylguanine-DNA methyltransferase (MGMT) within the tumor tissue, which leads to drug resistance and consequently reduces the efficacy of chemotherapy. SOB102 is an exosome-based nucleic acid drug with HLA-G targeting capabilities. The encapsulated nucleic acid drug inhibits MGMT activity within GBM cells, thereby increasing the sensitivity of tumor cells to chemotherapy drugs. Separately, by encapsulating and specifically targeting chemotherapy drugs with exosomes, the side effects of chemotherapy drugs can be reduced, enhancing overall safety.

The product highlights of SOB102 are as follows:
1. Highly Specific Targeting with HLA-G: HLA-G serves as a highly specific cancer immune checkpoint, allowing for the effective and safe delivery of loaded drugs directly to the tumor site.
2. Exosome Penetration of the Blood-Brain Barrier: Exosomes have the unique ability to traverse the blood-brain barrier, facilitating the effective delivery of nucleic acid drugs and thereby effectively re-sensitize tumor cells response to chemotherapy.
3. Innovative Exosome-Based Therapy for GBM Treatment: SOB102 provides a solution for the clinical challenges posed by drug-resistant GBM, a type of highly aggressive brain cancer.